



Pioneering cellular medicines for women's health

Biotech Showcase || January 2026

Dr Vera Evtimov
Director of Operations

Targeting Ovarian Cancer and Endometriosis

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD. ACN: 602 297 807

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such as ‘could,’ ‘would,’ ‘may,’ ‘potentially,’ ‘suggest,’ ‘believes,’ ‘expects,’ ‘should,’ ‘intends,’ ‘plans,’ ‘forecasts,’ and similar words or expressions.

Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including without limitation statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, pricing, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

The Company does not warrant any of the forward-looking statements in this presentation, and investors are advised to interpret such statements in the context of other available sources of information and with the assistance of expert advisors as appropriate.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Drug development is inherently risky, and only a small proportion of research and development programs lead to a marketed product. Factors which could change the Company’s expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the

ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; changes in the competitive landscape pertaining to our drug development candidates; the timely availability of necessary capital to pursue our business objectives; changes in the public policy environment in one or more countries in which we operate or may seek to operate which disfavours our business; our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services; and other factors, including the COVID-19 pandemic and the conflicts in Ukraine and Middle East.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, and although they reflect our current views as at the date of this presentation, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to pursue any specific strategy or plan outlined herein, or to deliver any specific outcome that may be implied or inferred.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

A Solid Foundation Built for Clinical Execution and Growth

Platform



Capability



Facility



Team



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Solid Foundation Built for Clinical Execution and Growth

Platform

- iPSC gene-editing & clone selection
- Engineering for persistence & safety
- iPSC to immune cell differentiation – clinical scale

Capability



Facility



Team



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Solid Foundation Built for Clinical Execution and Growth

Platform



Capability

- > US\$50M raised to date
- De-risked platform
- Established asset base – products, manufacturing facilities, IP portfolio

Facility



Team



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Solid Foundation Built for Clinical Execution and Growth

Platform



Capability



Facility

- State-of-the-art purpose built
- 2000 sq ft
- GMP-ready cleanrooms to drive our clinical programs to FIH

Team



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

A Solid Foundation Built for Clinical Execution and Growth

Platform



Capability



Facility



Team

- Dedicated
- ~30 experts
- Cell therapy, immunology, process development
- Led by recognized leaders

The Crippling Burden of Neglected Women's Health

A Two-Part Crisis in Women's Health

1 Ovarian Cancer: A Lethal Disease of Late Diagnosis

Diagnosis
increase of
55%
2022 to 2025

Mortality rate
increase by
70%
2022 to 2050

Target specific antigens
common to both
diseases

2 Endometriosis: Debilitating Disease

Leading cause



Pain



Organ
damage




Infertility

Our strategy leverages a de-risked entry in ovarian cancer
as a gateway to treating the broader endometriosis crisis


Our Pipeline: A Phased Approach to Value Creation

A Deliberate Strategy:
Validate the Platform, Then Unleash its Full Potential



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Robust IP Protecting Cartherics' Core Innovations



Patented Innovations

- Novel CAR constructs
- Proprietary gene edits
- Engineered iPSC Platform
- Further innovations

Valuable Trade Secrets

- Methods for feeder-free differentiation of iPSCs to functional immune cells

IN-LICENSED IP / TECHNOLOGY PARTNERS:



Catalent logos/trademarks that appear are the property (with all rights reserved) of Catalent, Inc. and/or its affiliates/subsidiaries.

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

Scalable Manufacturing for Clinical Success and Commercial Launch

A De-Risked, Hybrid Manufacturing Strategy



In-house: Clinical Supply & Process Mastery

- Focus: control, speed, IP protection
- Capability: discovery to clinic
- Provide material for early phase trials



Outsource: Large-scale Clinical & Commercial Scale

- Focus: scalability of manufacture
- Capability: access to large-scale infrastructure
- Provide “infinite”, on-demand supply

Our dual strategy provides maximum flexibility and control, ensuring a secure and scalable supply chain from first-in-human trials to global commercialization

Catalent logos/trademarks that appear are the property (with all rights reserved) of Catalent, Inc. and/or its affiliates/subsidiaries.

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICSPHY LTD.

Use of Funds: Accelerating Our Pipeline to Key Clinical Milestones

The Ask: Seeking **US\$15M** to fully fund operations through to key clinical and pre-clinical inflection points across our pipeline to the end of FY2027

Allocation of Capital

- Achieve clinical proof-of-concept for CTH-401
- Propel next-generation CTH-501 & CTH-502 to the clinic
- Advance core Platform & operations

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

The Investment Opportunity

Why Now?

- World-Class Team & Capabilities
- Clear Path to Value Creation
- A Focused Strategy
- De-Risked & Differentiated Science

Join us in **transforming** the standard of care for women's health

Dr Ian Nisbet
Chief Executive Officer
ian.nisbet@cartherics.com

Dr Vera Evtimov
Director of Operations
vera.evtimov@cartherics.com

 [cartherics.com](https://www.cartherics.com)

 [linkedin.com/company/cartherics-pty-ltd/](https://www.linkedin.com/company/cartherics-pty-ltd/)

 [youtube.com/watch?v=6tOtMMDaIs&t=10s](https://www.youtube.com/watch?v=6tOtMMDaIs&t=10s)

TERRAINCAPITAL

Corporate Advisor
Dominic Marinelli
Terrain Capital Limited
M: +61 405 269 536
dmarinelli@terraincapital.com